Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443093 | 0.89 | GRIN2B (0.36) | GRIN2BGRIN2CJAK3CTSKPKM | |
| SCHEMBL12386413 | 0.87 | GRIN2B (0.36) | GRIN2BGRIN2CJAK3CTSKEPHX1 | |
| SCHEMBL2302513 | 0.87 | GRIN2B (0.36) | GRIN2BGRIN2CJAK3CTSKEPHX1 | |
| SCHEMBL14282561 | 0.86 | GRIN2B (0.35) | GRIN2BGRIN2CJAK3CTSKEPHX1 | |
| SCHEMBL1949227 | 0.86 | GRIN2B (0.35) | GRIN2BGRIN2CJAK3CTSKEPHX1 | |
| SCHEMBL21238733 | 0.83 | GRIN2B (0.36) | GRIN2BGRIN2CJAK3CTSK | |
| SCHEMBL21238731 | 0.83 | GRIN2B (0.34) | GRIN2BGRIN2CJAK3CTSK | |
| SCHEMBL15936852 | 0.83 | GRIN2B (0.38) | GRIN2BGRIN2CJAK3CTSKCHRM2 | |
| SCHEMBL25297924 | 0.82 | GRIN2B (0.37) | GRIN2BGRIN2CJAK3CTSKCHRM2 | |
| SCHEMBL20437959 | 0.81 | GRIN2B (0.37) | GRIN2BGRIN2CJAK3CTSKEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998959-B2 | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same | INCYTE CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998959-B2 | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same | INCYTE CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998959-B2 | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same | INCYTE CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-20070197506-A1 | Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same | INCYTE CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197506-A1 | Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same | INCYTE CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197506-A1 | Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same | INCYTE CORPORATION | 2007-08-23 | — | — | US | disclosed |
| WO-2007084314-A2 | MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084314-A2 | MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197506-A1 | Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same | HSD11B1, HSD17B1, HSD3B1 | GRIN2B 2088/4885GRIN2C 1792/4885JAK3 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.